Medical devices and healthcare corporation Abbott Laboratories (NYSE:ABT) recently announced that its new cardiac mapping platform, the EnSite™ X EP System with EnSite Omnipolar Technology (OT), has received clearance from the U.S. Food and Drug Administration (FDA). The mapping platform is aimed at assisting doctors to better treat abnormal heart rhythms. Following the news, shares of the company declined 1.5% on Wednesday. The stock pared its loss slightly to close at $133.76 in the extended trading session.
https://www.tipranks.com/news/abbotts-cardiac-mapping-system-receives-fda-approval?utm_source=advfn.com&utm_medium=referral
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Avr 2022 à Mai 2022 Plus de graphiques de la Bourse Abbott Laboratories
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Mai 2021 à Mai 2022 Plus de graphiques de la Bourse Abbott Laboratories